MW07

MW07 is a **preclinical anti-SARS-CoV-2 monoclonal antibody** reported by Mabwell that binds the **receptor-binding domain of the SARS-CoV-2 spike protein** and neutralizes viral entry by blocking spike interaction with **angiotensin-converting enzyme 2**. Published structural and functional studies describe MW07 as a neutralizing antibody that binds the spike trimer only when the RBD is in the **up** conformation, in contrast to related antibodies MW01 and MW05, and notably report that MW07 **did not show antibody-dependent enhancement activity** in the in vitro systems used in those studies. Public drug intelligence sources list the program as **preclinical** for **COVID-19**, with Mabwell identified as the originator organization.